Loading
Persistent, recurrent or metastatic cervical cancer, PD-L1 CPS 1 or above
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Pembrolizumab Monoclonal antibody (anti-PD-1) | 200 mg | IV | D1 | or 400 mg every 6 weeks |
Paclitaxel Cytotoxic chemotherapy (taxane) | 175 mg/m² | IV | D1 | |
Cisplatin 50 mg/m² or carboplatin AUC 5 Cytotoxic chemotherapy (platinum) | day 1 | IV | D1 | |
Bevacizumab (optional) Monoclonal antibody (anti-VEGF) | 15 mg/kg | IV | D1 |
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.